The board of directors of Cutia Therapeutics announced that the investigational new drug (IND) application of CU-10101 (topical novel small molecule agent) of the Group, for the treatment of mild to moderate atopic dermatitis has been accepted by the Center for Drug Evaluation of the National Medical Products Administration of the People's Republic of China. CU-10101 is a non-hormonal, small molecule drug for the treatment of moderate atopic dermatitis. For atopic dermatitis, the therapeutic options are limited and mainly include corticosteroids, calcineurin inhibitors, systemic immunosuppressants, and targeted biologics and small-molecule drugs.

Localized topical corticosteroids are the most commonly prescribed therapies for atopic dermatitis. Most targeted biologics and small molecule drugs for atopic dermatitis require subcutaneous or oral administration, where systemic exposure causes a higher risk of side effects and lower patient compliance than localized topical application. The non-hormonal properties of CU-10101 may reduce the side effects and restrictions associated with corticosteroids and its localized topical formulation allows the medication to reach the affected areas directly.